We are each different, each "individual." So why should decisions be made about us - such as the drugs and treatments we need - be based on common (a.k.a. average) practices and 'Big Data' which tries to compare our individuality to some statistical mean?"
Big data creates data-driven models based on past experiences of populations to make broad predictions about future ones. As good as statistics can be, they rely on the assumption that the past will point the way to the future rather than truly understanding all of the moving parts that contribute to the future.
Bodylogical® is PwC’s scientifically-developed predictive engine that mechanistically simulates the human body and its functions. Currently focused on chronic lifestyle diseases, this engine mirrors the body’s own physiological systems—circulatory, respiratory, digestive, endocrine, renal, and more—to create a unique model of every unique life.
This model is dynamic. If a drug or lifestyle intervention makes a change to one system or even multiple systems, Bodylogical® quickly computes the impact on other systems and the overall health of the body.
The model has been successfully calibrated to represent drug and lifestyle response in thousands of Japanese patients. Our testing and validation approach and findings have been presented at international scientific conferences.
The cost of getting a new drug to market is unsustainable. Only a fraction of the drugs that are tested make it into the market. Running virtual clinical trials with Bodylogical® throughout drug development allows researchers to test hypotheses with the potential to improve the probability of success, thereby cutting invaluable time and expense out of the drug discovery process.
Once a drug is in the market, Bodylogical® allows simulating the effects of lifestyle and drug adherence on efficacy in real world conditions to help identify additional indications of a single disease state’s contribution to a larger group of comorbidities, identify undiagnosed patient cohorts and build additional effect hypotheses which can all lead to maximizing outcomes for patients.
The cost of poor health affects patients first. After that, it falls to the organizations that assume the financial risk of people becoming ill. Using health’s Big Data together with Bodylogical® to simultaneously simulate a large number of unique individual health trajectories brings new insights into how a population responds to health interventions. Payers can target those at risk and those likely to respond to interventions thereby optimizing a health and social return on investment.
Productivity losses and care costs related to absenteeism are a major concern for large employers. Employers can leverage Japan’s health-checkup data with Bodylogical to better monitor and manage the health and wellness of individual employees.
Bodylogical® can work with health data from wearables, connected health devices and your medical records customizing to your individual uniqueness through apps that help you identify the specific things that can deliver the most improvement for you and for those that matter to you the most.
Bodylogical® bridges the gap between improvement and perfection by giving clear line of sight to optimised recovery and potential peak performance letting athletes simulate all possible training options to custom-pick the ones that works the best for them.
© 2004 - Wed Dec 12 10:32:46 UTC 2018 PwC. All rights reserved. PwC refers to the PwC network and/or one or more of its member firms, each of which is a separate legal entity. Please see www.pwc.com/structure for further details.